Pieris Pharmaceuticals Revenue 2014-2021 | PIRS

Pieris Pharmaceuticals revenue from 2014 to 2021. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Pieris Pharmaceuticals Annual Revenue
(Millions of US $)
2020 $29
2019 $46
2018 $29
2017 $25
2016 $6
2015 $3
2014 $5
2013 $12
Pieris Pharmaceuticals Quarterly Revenue
(Millions of US $)
2021-06-30 $3
2021-03-31 $16
2020-12-31 $2
2020-09-30 $3
2020-06-30 $11
2020-03-31 $13
2019-12-31 $17
2019-09-30 $15
2019-06-30 $5
2019-03-31 $9
2018-12-31 $5
2018-09-30 $8
2018-06-30 $12
2018-03-31 $4
2017-12-31 $18
2017-09-30 $4
2017-06-30 $2
2017-03-31 $1
2016-12-31 $3
2016-09-30 $1
2016-06-30 $1
2016-03-31 $1
2015-12-31 $2
2015-09-30 $0
2015-06-30 $0
2015-03-31 $0
2014-12-31 $3
2014-09-30 $0
2014-06-30 $1
2014-03-31 $1
2013-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.375B $0.029B
Pieris Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's drug technology consists of Anticalin(R) to treat cancer, severe asthma, anemia and other medical conditions. Pieris Pharmaceuticals, Inc. is based in Freising-Weihenstephan, Germany.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.838B 8.91
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.341B 20.90
Biohaven Pharmaceutical Holding (BHVN) United States $8.723B 0.00
Emergent Biosolutions (EBS) United States $2.813B 6.79
Arcus Biosciences (RCUS) United States $2.568B 0.00
Myovant Sciences (MYOV) United Kingdom $2.170B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.949B 0.00
Zymeworks (ZYME) Canada $1.323B 0.00
Ambrx Biopharma (AMAM) United States $0.509B 0.00
SQZ Biotechnologies (SQZ) United States $0.428B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29